Tag: AGEN

Finance

Gainers at Biotech: Alcobra (NASDAQ:ADHD), Aratana Therapeutics (NASDAQ:PETX), Northwest Biotherapeutics (NASDAQ:NWBO), Agenus Inc (NASDAQ:AGEN), AEterna Zentaris (NASDAQ:AEZS)

Research analysts at WBB Securities initiated coverage on shares of Alcobra Ltd (NASDAQ:ADHD) in a report released on Thursday, 26 June 2014. The firm set a “hold” rating and a $18.00 price target on the stock. WBB Securities’ target price points to a potential upside of 5.76% from the company’s current price. Alcobra Ltd (NASDAQ:ADHD) stock performance was 5.85% in last session and finished the … Continue reading Gainers at Biotech: Alcobra (NASDAQ:ADHD), Aratana Therapeutics (NASDAQ:PETX), Northwest Biotherapeutics (NASDAQ:NWBO), Agenus Inc (NASDAQ:AGEN), AEterna Zentaris (NASDAQ:AEZS)

Jayne Crisman
Finance

Healthcare Active Movers: Pfizer Inc. (NYSE:PFE), MannKind Corporation (NASDAQ:MNKD), Gilead Sciences (NASDAQ:GILD), Agenus (NASDAQ:AGEN), Merck & Co (NYSE:MRK)

Spirits maker Diageo North America and pharmaceutical giant Pfizer Inc. (NYSE:PFE) have each agreed to pay a $5,000 fine because their lobbyists failed to disclose expenditures for receptions at the 2012 Democratic National Convention, the Office of State Ethics announced. Pfizer Inc. (NYSE:PFE) stock performance was 1.35% in last session and finished the day at $30.08. Traded volume was 25.60million shares in the last session … Continue reading Healthcare Active Movers: Pfizer Inc. (NYSE:PFE), MannKind Corporation (NASDAQ:MNKD), Gilead Sciences (NASDAQ:GILD), Agenus (NASDAQ:AGEN), Merck & Co (NYSE:MRK)

Kristen Barton
Finance

Biotech Bearish Stocks: Zalicus Inc (NASDAQ:ZLCS), Stemline Therapeutics Inc (NASDAQ:STML), Agenus Inc (NASDAQ:AGEN), Arrowhead Research Corp (NASDAQ:ARWR), Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

Zalicus Inc (NASDAQ:ZLCS) on June 18 announced that it has licensed its Sodium Channel Modulator program, including intellectual property and related pipeline assets, to AnaBios Corporation in exchange for clinical milestone payments and royalties on potential future sales. Under the terms of the agreement Zalicus will be eligible to receive up to $17.2 million in clinical and regulatory milestone payments and up to 12% of … Continue reading Biotech Bearish Stocks: Zalicus Inc (NASDAQ:ZLCS), Stemline Therapeutics Inc (NASDAQ:STML), Agenus Inc (NASDAQ:AGEN), Arrowhead Research Corp (NASDAQ:ARWR), Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

Kevin Long
BioTech

Biotech Early Movers: OncoGenex Pharmaceuticals Inc(NASDAQ:OGXI), Agenus Inc(NASDAQ:AGEN), Athersys, Inc.(NASDAQ:ATHX)

OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) shares plunged more than 48% pre-market after the company said results from its Phase 3 SYNERGY trial to add custirsen to standard first-line treatment of docetaxel/prednisone in men with metastatic prostate cancer failed to meet primary endpoints. The stock which was halted from trading ahead of the news, recently changed hands at $5.00, off an earlier low of $4.25. The shares … Continue reading Biotech Early Movers: OncoGenex Pharmaceuticals Inc(NASDAQ:OGXI), Agenus Inc(NASDAQ:AGEN), Athersys, Inc.(NASDAQ:ATHX)

Colin Pettis
Finance

Biotech Volatile Stocks: NewLink Genetics Corp (NASDAQ:NLNK), Alnylam Pharmaceuticals (NASDAQ:ALNY), Kindred Biosciences (NASDAQ:KIN), Agenus (NASDAQ:AGEN)

NewLink Genetics Corp (NASDAQ:NLNK)’s algenpantucel-L is expected to garner the highest sales and will be launched in both resectable and unresectable locally-advanced settings. Other drugs with significant forecast sales by 2017 include Threshold Pharmaceuticals/Merck’s TH-302 and Merrimack Pharmaceuticals’ MM-398,” director says. NewLink Genetics Corp (NASDAQ:NLNK) stock performance was -9.03% in last session and finished the day at $24.98. Traded volume was 808,573.00million shares in the … Continue reading Biotech Volatile Stocks: NewLink Genetics Corp (NASDAQ:NLNK), Alnylam Pharmaceuticals (NASDAQ:ALNY), Kindred Biosciences (NASDAQ:KIN), Agenus (NASDAQ:AGEN)

John Bellich
FB Nasdaq FB Facebook
Finance

Biotech Losers: Agenus Inc (NASDAQ:AGEN), La Jolla Pharmaceutical Company (NASDAQ:LJPC), Durata Therapeutics (NASDAQ:DRTX), Galmed Pharmaceuticals (NASDAQ:GLMD)

Shares of Agenus Inc (NASDAQ:AGEN) , a biopharmaceutical company focused on developing novel immunotherapies to treat cancer and a number of other unmet diseases, tumbled by as much as 22% after partner GlaxoSmithKline (NYSE: GSK ) announced that its phase 3 MAGE-A3 cancer immunotherapeutic trial in non-small cell lung cancer (NSCLC) patients didn’t meet its first or second coprimary endpoint. Agenus Inc (NASDAQ:AGEN) stock performance … Continue reading Biotech Losers: Agenus Inc (NASDAQ:AGEN), La Jolla Pharmaceutical Company (NASDAQ:LJPC), Durata Therapeutics (NASDAQ:DRTX), Galmed Pharmaceuticals (NASDAQ:GLMD)

Kevin Long